Open Access iconOpen Access

REVIEW

crossmark

Ubiquitin-like posttranslational modifications in NAFLD progression and treatment

FUJI YANG1, YAN HUANG1, YOUWEN TAN2,*, YONGMIN YAN1,*

1 Key Laboratory of Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, 212013, China
2 The Affiliated Third Hospital of Zhenjiang, Jiangsu University, Zhenjiang, 212013, China

* Corresponding Authors:YONGMIN YAN, email; YOUWEN TAN, email

(This article belongs to this Special Issue: Stem Cells, Protein Therapeutics, and Regenerative Medicine)

BIOCELL 2022, 46(2), 389-400. https://doi.org/10.32604/biocell.2021.015899

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a long-lasting condition that affects the liver, destroying its function. Liver injury can cause steatosis and inflammation, and further activation of hepatic stellate cells (HSCs) often leads to the development of nonalcoholic liver fibrosis. The patient with NAFLD is at risk of developing advanced liver disease and complications, such as liver failure, hepatocellular carcinoma (HCC), and portal hypertension. Although our understanding of the cellular and molecular mechanisms of NAFLD has greatly improved in recent years, treatment remains limited. Analysis and characterization of protein posttranslational modifications (PTMs) could improve our understanding of NAFLD pathology and leading to the development of new and more effective treatments. In recent years, a number of studies have described how ubiquitin-like (Ubl)-PTMs change during NAFLD and how treatments targeting specific enzymes mediating these Ubl-PTMs can improve various liver diseases, particularly in relation to NAFLD and nonalcoholic liver fibrosis. New strategies for evaluating modified proteomes could provide novel insights into the roles of Ubl-PTMs in NAFLD progression and the therapeutic value of targeting the proteins involved in these Ubl-PTMs.

Keywords


Cite This Article

YANG, F., HUANG, Y., TAN, Y., YAN, Y. (2022). Ubiquitin-like posttranslational modifications in NAFLD progression and treatment. BIOCELL, 46(2), 389–400.



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 3161

    View

  • 1698

    Download

  • 0

    Like

Share Link